Atossa Genetics Inc  

(Public, NASDAQ:ATOS)   Watch this stock  
Find more results for ATOS
-0.005 (-0.80%)
Real-time:   2:53PM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.61 - 0.65
52 week 0.22 - 1.65
Open 0.63
Vol / Avg. 1.47M/8.47M
Mkt cap 19.73M
P/E     -
Div/yield     -
EPS -1.93
Shares 31.82M
Beta 3.01
Inst. own 9%
Mar 29, 2018
Q4 2017 Atossa Genetics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -210.02% -122.62%
Return on average equity -326.55% -186.26%
Employees 2 -
CDP Score - -


107 Spring St
SEATTLE, WA 98104-1005
United States - Map
+1-206-5880256 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Atossa Genetics Inc. is a clinical-stage pharmaceutical company focused on the development of therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The Company's leading program uses its intraductal microcatheters, which deliver pharmaceuticals through the breast ducts. It has initiated a Phase II clinical study using its microcatheters to deliver fulvestrant as a treatment of ductal carcinoma in-situ (DCIS) and breast cancer. Its second pharmaceutical program under development is Afimoxifene Topical Gel (AfTG) for the treatment and prevention of hyperplasia of the breast. It is also engaged in the process of evaluating other therapeutic candidates to treat other breast conditions, including breast cancer. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator. These devices are intended for the collection of nipple aspirate fluid (NAF) for cytological testing at a laboratory.

Officers and directors

Steven C. Quay M.D., Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Kyle Guse Esq., CPA Chief Financial Officer, General Counsel, Secretary
Age: 51
Bio & Compensation  - Reuters
Cindy Atha Vice President of Sales and Marketing
Bio & Compensation  - Reuters
Janet Rose Rea MSPH Vice President - Regulatory Affairs and Quality
Bio & Compensation  - Reuters
Shu-Chih Chen Ph.D. Director
Age: 53
Bio & Compensation  - Reuters
Stephen J. Galli M.D. Independent Director
Age: 68
Bio & Compensation  - Reuters
H. Lawrence Remmel Esq. Independent Director
Age: 63
Bio & Compensation  - Reuters
Richard I. Steinhart CPA Independent Director
Age: 59
Bio & Compensation  - Reuters
Gregory L. Weaver Independent Director
Age: 61
Bio & Compensation  - Reuters